Positive News SentimentPositive NewsNASDAQ:INVA Innoviva (INVA) Stock Price, News & Analysis $21.44 +0.24 (+1.13%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$21.42 -0.02 (-0.09%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Innoviva Stock (NASDAQ:INVA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Innoviva alerts:Sign Up Key Stats Today's Range$21.29▼$21.4950-Day Range$21.20▼$23.6452-Week Range$16.52▼$25.15Volume550,443 shsAverage Volume881,886 shsMarket Capitalization$1.58 billionP/E Ratio3.57Dividend YieldN/APrice Target$36.20Consensus RatingModerate Buy Company Overview Innoviva, Inc., incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma. The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle. Since its formation, Innoviva has supplemented its core royalty stream with additional licensing and collaboration agreements, and has pursued disciplined capital‐allocation activities to maximize dividend payments to shareholders. The firm’s contractual arrangements typically provide for tiered royalties on net sales as well as potential milestone receipts upon regulatory approvals and commercial launches. Innoviva’s royalty revenues are generated globally through collaboration partners that market, distribute and promote the underlying therapeutics both in the United States and in international territories. The company maintains a lean corporate structure, relying on third‐party manufacturing, regulatory and commercialization expertise. Innoviva is governed by an experienced board of directors and led by management professionals with backgrounds in pharmaceutical licensing, royalty financing and capital markets.AI Generated. May Contain Errors. Read More Innoviva Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreINVA MarketRank™: Innoviva scored higher than 65% of companies evaluated by MarketBeat, and ranked 357th out of 836 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingInnoviva has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialInnoviva has a consensus price target of $36.20, representing about 68.8% upside from its current price of $21.44.Amount of Analyst CoverageInnoviva has only been the subject of 3 research reports in the past 90 days.Read more about Innoviva's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-2.27% Earnings GrowthEarnings for Innoviva are expected to decrease by -2.27% in the coming year, from $2.20 to $2.15 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Innoviva is 3.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.81.Price to Earnings Ratio vs. SectorThe P/E ratio of Innoviva is 3.57, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.14.Price to Book Value per Share RatioInnoviva has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Innoviva's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.70% of the float of Innoviva has been sold short.Short Interest Ratio / Days to CoverInnoviva has a short interest ratio ("days to cover") of 7.54.Change versus previous monthShort interest in Innoviva has recently increased by 5.57%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInnoviva does not currently pay a dividend.Dividend GrowthInnoviva does not have a long track record of dividend growth. News and Social Media4.3 / 5News Sentiment1.82 News SentimentInnoviva has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Innoviva this week, compared to 3 articles on an average week.Search Interest2 people have searched for INVA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Innoviva insiders have not sold or bought any company stock.Percentage Held by Insiders2.01% of the stock of Innoviva is held by insiders.Percentage Held by Institutions99.12% of the stock of Innoviva is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Innoviva's insider trading history. Receive INVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INVA Stock News HeadlinesMajor Theravance Biopharma Investor Makes Notable Stock MoveJuly 8, 2026 | tipranks.comMajor Insider Move Rocks Theravance Biopharma SharesJuly 1, 2026 | tipranks.comBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.July 26 at 1:00 AM | Decentralized Masters (Ad)Is Innoviva (INVA) One of the Best Cheap Small Cap Stocks to Buy Now?July 1, 2026 | insidermonkey.com5 Cheap Small Cap Stocks to Buy NowJune 30, 2026 | insidermonkey.comZymeworks Targets Long-Term Cash Generation Through Theravance AcquisitionJune 29, 2026 | benzinga.comZymeworks to Acquire Theravance in Strategic MergerJune 29, 2026 | tipranks.comTheravance Biopharma to be Acquired by ZymeworksJune 29, 2026 | tipranks.comSee More Headlines INVA Stock Analysis - Frequently Asked Questions How have INVA shares performed this year? Innoviva's stock was trading at $19.99 at the start of the year. Since then, INVA shares have increased by 7.3% and is now trading at $21.44. How were Innoviva's earnings last quarter? Innoviva, Inc. (NASDAQ:INVA) announced its earnings results on Wednesday, May, 6th. The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.01. The biotechnology company earned $97.99 million during the quarter, compared to analyst estimates of $101.57 million. Innoviva had a net margin of 119.89% and a trailing twelve-month return on equity of 33.33%. Who are Innoviva's major shareholders? Innoviva's top institutional shareholders include CX Institutional (0.38%), Oliver Luxxe Assets LLC (0.08%) and GAMMA Investing LLC (0.01%). View institutional ownership trends. How do I buy shares of Innoviva? Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Innoviva own? Based on aggregate information from My MarketBeat watchlists, some other companies that Innoviva investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Visa (V). Company Calendar Last Earnings5/06/2026Today7/26/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 For the last 9 days, INVA's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Large Cap Pharma Sub-IndustryBiotechnology Current SymbolNASDAQ:INVA Previous SymbolNASDAQ:THRX CIK1080014 Webwww.inva.com Phone(650) 238-9600Fax650-827-8690Employees100Year Founded1996Price Target and Rating Average Price Target for Innoviva$36.20 High Price Target$46.00 Low Price Target$17.00 Potential Upside/Downside+68.8%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$6.01 Trailing P/E Ratio3.57 Forward P/E Ratio9.75 P/E GrowthN/ANet Income$271.17 million Net Margins119.89% Pretax Margin142.63% Return on Equity33.33% Return on Assets22.67% Debt Debt-to-Equity Ratio0.19 Current Ratio21.13 Quick Ratio20.07 Sales & Book Value Annual Sales$411.33 million Price / Sales3.85 Cash Flow$5.03 per share Price / Cash Flow4.26 Book Value$15.71 per share Price / Book1.36Miscellaneous Outstanding Shares73,810,000Free Float72,325,000Market Cap$1.58 billion OptionableOptionable Beta0.34 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:INVA) was last updated on 7/26/2026 by MarketBeat.com Staff. From Our PartnersThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThis tiny piece of glass could be bigger than GPUsJensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...Brownstone Research | SponsoredThe 90%-off options that empty accountsA call that cost $3.00 last month now trades for $0.30 - a 90% discount that looks tempting. It's not a bar...Profits Run | SponsoredHave you seen Elon’s new “supercurrency”? (It affects you)Elon Musk just became the world's first trillionaire following the biggest IPO in history, giving him access t...StocksToTrade | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innoviva, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innoviva With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
